Ipamorelin + HGH Fragment 176-191 Stack: Fat Loss Protocol and Dosing Guide

How Each Peptide Works

Ipamorelin is a third-generation growth hormone releasing peptide (GHRP) that selectively binds the ghrelin receptor (GHSR-1a) on pituitary somatotrophs, triggering the release of endogenous growth hormone. Unlike older GHRPs, ipamorelin does not elevate cortisol, prolactin, or appetite — it releases only GH, at any dose. When combined with a GHRH analog like CJC-1295, the GH release is synergistic (3–5x greater than either alone).

HGH Fragment 176-191 works through a completely different mechanism. It activates beta-3 adrenergic receptors (ADRB3) in white and brown adipose tissue, which triggers an intracellular cAMP cascade that activates protein kinase A (PKA) and hormone-sensitive lipase (HSL). This directly breaks down stored triglycerides into free fatty acids. A 2001 study in obese Zucker rats (Ng et al.) found that 20 days of AOD-9604 treatment reduced body weight gain, decreased average adipocyte diameter from 110 to 80 micrometers, and — critically — did not induce insulin resistance or glucose intolerance, unlike full-length growth hormone.

Stack Dosing Protocol

Critical timing rule: HGH fragment 176-191 must be injected on an empty stomach — no food for at least 1 hour before and 30 minutes after injection. Insulin from food intake directly inhibits hormone-sensitive lipase, which is the enzyme the fragment activates. Eating around the injection window blunts or eliminates the lipolytic effect.

Ipamorelin timing: Most effective when injected during natural GH pulse windows — morning (fasted), post-exercise, and before bed. The bedtime dose synergizes with the body's largest natural GH pulse, which occurs during the first 90 minutes of deep sleep.

Cycle Length and Expectations

Recommended cycle: 8–12 weeks for the full stack. HGH frag 176-191 can be run for 4–12 weeks; ipamorelin can be used long-term without desensitization.

Weeks 1–2: Most users notice improved sleep quality (from ipamorelin's GH pulse enhancement) and mild increase in energy. Fat loss effects are not yet visible.

Weeks 3–6: Measurable reduction in subcutaneous fat, particularly abdominal. Users typically report 1–2 lbs of fat loss per week when combined with a caloric deficit and exercise. Skin quality improvements from GH-mediated collagen synthesis.

Weeks 6–12: Cumulative body recomposition becomes clearly visible. Best results occur when the stack is combined with resistance training (preserves lean mass) and moderate caloric deficit (300–500 kcal/day). Aggressive caloric restriction is counterproductive — it suppresses natural GH output and thyroid function.

Women: Respond to lower doses of HGH frag 176-191 (200–400 mcg/day) and ipamorelin (100–200 mcg, 2x/day). The same timing rules apply.

Why This Stack Works Better Than Either Alone

The synergy comes from complementary mechanisms that don't interfere with each other:

• Ipamorelin raises GH → improves protein synthesis, muscle preservation, recovery, deep sleep, and overall metabolic rate. But GH alone is an indirect fat-loss mechanism — it has to be converted to IGF-1 and interact with fat cells through complex signaling.
• HGH frag 176-191 directly activates lipolysis → acts on fat cells through ADRB3 receptors, bypassing the GH-IGF-1 axis entirely. It doesn't raise IGF-1, doesn't affect blood sugar, and doesn't require GH to work.
• No interference: Because the fragment doesn't affect the GH axis or IGF-1, it doesn't blunt ipamorelin's effectiveness. And because ipamorelin works through the pituitary (not directly on fat cells), it doesn't compete with the fragment's ADRB3 pathway.

Adding CJC-1295 (no DAC) to the stack amplifies ipamorelin's GH release 3–5x through GHRH receptor synergy — making the three-peptide combination (ipamorelin + CJC-1295 + HGH frag) the most comprehensive GH + fat loss protocol available.

Side Effects and Monitoring

Common side effects: Injection site redness (transient), mild headache in the first week (usually resolves), and vivid dreams (from GH-enhanced deep sleep). These are typical of any GH-releasing peptide protocol.

What to monitor:

• Fasting glucose and insulin: HGH frag 176-191 should not affect these (unlike full GH), but ipamorelin-induced GH elevation can theoretically impair insulin sensitivity at high doses. Check baseline and at 6 weeks.
• IGF-1: Should rise modestly from ipamorelin (confirms the peptide is working). If IGF-1 rises excessively (>1.5x upper normal), reduce ipamorelin dose.
• Thyroid panel: Extended caloric deficits can suppress T3 independently of the peptides. Monitor if running the stack alongside aggressive dieting.